Sign in to view content

Number of Injections and Time to Dry Analysis of Brolucizumab Versus Aflibercept in Patients With Neovascular AMD: 96-Week Data From HAWK and HARRIER

Carl D. Regillo, MD

Video
Published 2020

Related

Intravitreal Gene Therapy for Neovascular AMD with ADVM-022: Results of the Phase 1 OPTIC Trial
Dante Joseph Pieramici, MD
Annual Meeting Talks
2021
Intravitreal Gene Therapy for Diabetic Macular Edema With ADVM-022: First-Time Data Presentation of Prospective, Randomized Phase 2 INFINITY Trial
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2021
Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial
Diana V Do, MD, FASRS
Updates from the Field
2024

Category: AMD-Neovascular

See more